Cantor Fitzgerald Reaffirms Their Hold Rating on Humana (HUM)
Cantor Fitzgerald analyst Sarah James maintained a Hold rating on Humana yesterday and set a price target of $201.00.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, James is a 4-star analyst with an average return of 3.7% and a 53.14% success rate. James covers the Healthcare sector, focusing on stocks such as CVS Health, Molina Healthcare, and Acadia Healthcare.
In addition to Cantor Fitzgerald, Humana also received a Hold from KeyBanc’s Matthew Gillmor CFA in a report issued today. However, on the same day, Oppenheimer maintained a Buy rating on Humana (NYSE: HUM).
Based on Humana’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $32.65 billion and a net profit of $195 million. In comparison, last year the company earned a revenue of $29.4 billion and had a net profit of $480 million
Read More on HUM:
Disclaimer & DisclosureReport an Issue
- Humana price target lowered to $146 from $174 at Morgan Stanley
- Humana price target lowered to $252 from $312 at Guggenheim
- RBC downgrades Humana on Medicare Advantage cost pressure
- Humana downgraded to Sector Perform from Outperform at RBC Capital
- Humana Earnings Call: Growth Prospects Versus STARS Hit
